Charcot-Marie-Tooth Type 1A Neuropathy Clinical Trial
— CCA1Official title:
Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A
| NCT number | NCT01750710 |
| Other study ID # | CHU-0128 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | December 2012 |
| Est. completion date | April 28, 2016 |
| Verified date | October 2019 |
| Source | University Hospital, Clermont-Ferrand |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This exploratory cross-sectional study proposes, firstly, to objectify in a population of Charcot-Marie-Tooth disease type 1A (CMT 1A)if there is a correlation between the recording of electrical parameters and upper limb muscle strength of the thigh and in a second step, to seek a relationship between the measured parameters.
| Status | Completed |
| Enrollment | 37 |
| Est. completion date | April 28, 2016 |
| Est. primary completion date | April 28, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients older than 18 years - Diagnosis of Charcot Marie Tooth disease, type 1A confirmed by molecular biology (duplication 17.p11.2) - Listening and written French - Agreement after written information, clear and honest about the purpose of the study, the nature of the tests and their possible side effects or bothersome. - Strength of the quadriceps superior to 2/5 MMT MRC Exclusion Criteria: - Presence of other neurological comorbidity - Presence of coronary artery disease unstabilized - Peripheral neuropathy of other causes: diabetes, monoclonal gammopathy, malignancy, solid cancer, systemic autoimmune disease (lupus, Sjögren's disease, Wegener sarcoidosis ...), infectious disease (viral hepatitis, HIV ...), drugs known to be responsible for iatrogenic neuropathy. - Gait trouble of other origin - Patients unable to give their consent. - Intellectual deficit that does not allow to comply with tests |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Clermont-Ferrand | Clermont-Ferrand |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Clermont-Ferrand |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | axonal loss | at day 1 | ||
| Secondary | Muscle strength | at day 1 | ||
| Secondary | Functional scores | at day 1 | ||
| Secondary | Hand testing | at day 1 | ||
| Secondary | spatial and temporal parameters of walking | at day 1 | ||
| Secondary | Barometric stabilometric podo-static scores | at day 1 | ||
| Secondary | Quality of life | at day 1 | ||
| Secondary | Fatigue | at day 1 | ||
| Secondary | Depression | at day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05142059 -
Fall Risk Assessment in a Population of Charcot-Marie-Tooth Disease Type 1A (CMT 1A) by Timed Up and Go Test
|
N/A |